早期口腔舌癌辅助放疗:基于NCDB分级的见解
本研究利用美国国家癌症数据库(2004-2022)回顾性分析3562例pT1-2N0M0口腔舌鳞状细胞癌患者,其中456例(12.8%)接受术后放疗(PORT)。倾向性评分匹配后,PORT在低分化肿瘤中与生存获益相关(HR 0.53,95%CI 0.30-0.92,p=0.025),多变量分析及排除淋巴血管侵犯后仍持续;而在高、中分化肿瘤中未见总生存获益。
要点
- 低分化早期口腔舌癌PORT与生存获益相关(HR 0.53)。
- 高、中分化肿瘤中PORT未改善总生存。
- 作者认为需前瞻性研究优化风险分层和指南。
核心结论
- PORT在低分化早期口腔舌鳞状细胞癌中与生存获益相关,验证并扩展了既往国际数据。
- 高、中分化肿瘤中未见PORT获益,强调个体化治疗的必要性。
- 作者认为需前瞻性研究以完善风险分层和优化临床指南。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库(2004-2022)数据。
- 纳入经严格筛选的pT1-2N0M0口腔舌鳞状细胞癌患者3562例,其中456例(12.8%)接受PORT。
- 采用倾向性评分匹配平衡关键预后因素,使用Kaplan-Meier分析和多变量Cox比例风险模型评估生存。
主要发现
- PORT未改善高分化或中分化肿瘤的总生存。
- 低分化肿瘤中,PORT与显著生存获益相关(HR 0.53,95%CI 0.30-0.92,p=0.025),倾向性评分匹配前后一致。
- 多变量分析中该效应持续(HR 0.56,95%CI 0.31-0.99,p=0.047)。
- 排除淋巴血管侵犯患者后该效应仍存在(HR 0.48,95%CI 0.27-0.87,p=0.016)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral tongue squamous cell carcinoma (OTSCC) incidence is rising in the United States. While early-stage (pT1-2N0M0) OTSCC is primarily managed with surgery, the role of postoperative radiotherapy (PORT) remains debated, particularly in moderate-to-poor differentiation. Current guidelines do not recommend PORT based on histologic grade alone, yet a retrospective study by Tian et al. found PORT improved survival in moderately-to-poorly differentiated OTSCC in a Chinese cohort. We aimed to validate these findings in a US population. METHODS: A retrospective cohort study using the National Cancer Database (2004-2022) identified patients with pT1-2N0M0 OTSCC treated with surgery or surgery plus PORT. After stringent inclusion criteria, 3562 patients remained, including 456 (12.8%) who received PORT. Propensity score matching (PSM) balanced key prognostic factors, and survival was assessed using Kaplan-Meier analysis and multivariable Cox proportional hazards models. RESULTS: PORT did not improve OS in well- or moderately differentiated tumors. However, in poorly differentiated tumors, PORT was associated with a significant survival benefit (HR: 0.53, 95% CI: 0.30-0.92, p = 0.025) before and after PSM. This effect persisted in multivariable analysis (HR: 0.56, 95% CI: 0.31-0.99, p = 0.047) and after excluding patients with lymphovascular invasion (HR: 0.48, 95% CI: 0.27-0.87, p = 0.016). CONCLUSIONS: These findings validate and extend prior international data, demonstrating a PORT-associated survival benefit in poorly differentiated early-stage OTSCC. The lack of benefit in well- and moderately differentiated tumors underscores the need for individualized treatment approaches. Prospective studies are warranted to refine risk stratification and optimize clinical guidelines.
引用
- Nolasco B, Brodin NP, Samuel N, et al. Adjuvant Radiotherapy for Early-Stage Oral Tongue Cancer: Insights From the NCDB Based on Grade. Head Neck. 2025. PMID: 40657806. doi:10.1002/hed.28243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。